Claims
- 1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NO: 64-77.
- 2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) sequences having at least 75% identity to a sequence recited in SEQ ID NO: 61-77; (b) sequences having at least 90% identity to a sequence recited in SEQ ID NO: 61-77 ; and (c) sequences having at least 95% identity to a sequence recited in SEQ ID NO: 61-77.
- 3. An isolated polynucleotide encoding a polypeptide according to any one of claims 1 and 2.
- 4. The isolated polynucleotide of claim 3, wherein the polynucleotide comprises a sequence selected from the group consisting of sequences recited in SEQ ID NO: 8-21.
- 5. An isolated polynucleotide comprising a sequence selected from the group consisting of:
(a) sequences having at least 75% identity to a sequence recited in SEQ ID NO: 8-21; (b) sequences having at least 90% identity to a sequence recited in SEQ ID NO: 8-21; (c) sequences having at 95% identity to a sequence recited in SEQ ID NO: 8-21; (d) complements of a sequence recited in SEQ ID NO: 8-21; and (e) complements of a sequence of (a), (b) or (c).
- 6. A genetic construct comprising at least one polynucleotide according to any one of claims 3-5.
- 7. The genetic construct of claim 6, wherein the construct comprises a sequence selected from the group consisting of SEQ ID NO: 56-58 and 82-89.
- 8. A host cell transformed with a genetic construct according to any one of claims 6 and 7.
- 9. A fusion protein comprising at least one polypeptide according to any one of claims 1 and 2.
- 10. The fusion protein of claim 9, wherein the fusion protein comprises a sequence selected from the group consisting of: SEQ ID NO: 79-81, 90-97 and 116.
- 11. A polynucleotide encoding a fusion protein of claim 9, wherein the polynucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 56-58, 82-89 and 115.
- 12. A composition comprising at least one polypeptide according to any one of claims 1 and 2, and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
- 13. A composition comprising at least one polynucleotide according to any one of claims 3-5 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
- 14. A composition comprising at least one fusion protein according to claim 9 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
- 15. The composition of claim 14, wherein the composition further comprises a flt3 ligand.
- 16. A composition comprising at least one genetic construct according to claim 6, and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.
- 17. A method for enhancing an immune response in a patient, comprising administering to the patient a composition according to any one of claims 11-16.
- 18. The method of claim 17, wherein the immune response is a Th1 response.
- 19. The method of claim 17, wherein the composition activates at least one cell selected from the group consisting of T cells and NK cells.
- 20. The method of claim 17, wherein the composition stimulates cytokine production.
- 21. The method of claim 17, wherein the composition induces long-term memory cells.
- 22. A method for the treatment of a disorder selected from the group consisting of immune disorders, infectious diseases and cancer in a patient, comprising administering to the patient a composition according to any one of claims 11-16.
- 23. The method of claim 22, wherein the disorder is tuberculosis.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/NZ00/00121 |
Jul 2000 |
WO |
|
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 10/100,679, filed Mar. 14, 2002; which is a continuation-in-part of U.S. patent application Ser. No. 09/450,072, filed Nov. 29, 1999, now U.S. Pat. No. 6,358,734; which is a continuation-in-part of U.S. patent application Ser. No. 09/351,348, filed Jul. 12, 1999, now U.S. Pat. No. 6,436,898, and claims priority to PCT International Patent Application PCT/NZ00/00121 filed on Jul. 10, 2000.
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
10100679 |
Mar 2002 |
US |
Child |
10607752 |
Jun 2003 |
US |
Parent |
09450072 |
Nov 1999 |
US |
Child |
10100679 |
Mar 2002 |
US |
Parent |
09351348 |
Jul 1999 |
US |
Child |
09450072 |
Nov 1999 |
US |